Grifols Shares Outstanding 2012-2018 | GRFS

Grifols shares outstanding history from 2012 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Grifols shares outstanding for the quarter ending September 30, 2018 were 0.000B, a 100% decline year-over-year.
  • Grifols 2017 shares outstanding were 0.684B, a 0.15% increase from 2016.
  • Grifols 2016 shares outstanding were 0.683B, a 0.35% decline from 2015.
  • Grifols 2015 shares outstanding were 0.686B, a 0.12% decline from 2014.
Grifols Annual Shares Outstanding
(Millions of Shares)
2017 684
2016 683
2015 686
2014 687
2013 684
2012 685
2011 556
Grifols Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 0
Q2 2018 675
Q2 2017 685
Q1 2017 670
Q4 2016 683
Q3 2016 675
Q2 2016 696
Q1 2016 696
Q4 2015 0
Q3 2015 683
Q2 2015 682
Q1 2015 676
Q4 2014 691
Q3 2014 692
Q2 2014 692
Q1 2014 691
Q4 2013 714
Q3 2013 674
Q2 2013 673
Q1 2013 663
Q4 2012 791
Q3 2012 670
Q2 2012 693
Q1 2012 675
Q4 2011 912
Q3 2011 572
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $13.311B $4.878B
Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $40.641B 27.83
Takeda Pharmaceutical (TAK) Japan $30.903B 14.44
Neurocrine Biosciences (NBIX) United States $8.300B 1830.60
Nektar Therapeutics (NKTR) United States $7.997B 11.46
Ionis Pharmaceuticals (IONS) United States $7.983B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.786B 11.18
Tilray (TLRY) United States $7.192B 0.00
Loxo Oncology (LOXO) United States $7.148B 0.00
Sage Therapeutics (SAGE) United States $6.554B 0.00
Catalent (CTLT) United States $5.177B 21.71
United Therapeutics (UTHR) United States $5.045B 8.25
FibroGen (FGEN) United States $4.480B 0.00
TESARO (TSRO) United States $4.126B 0.00
Impax Laboratories (AMRX) United States $3.708B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.700B 13.70
USANA Health Sciences (USNA) United States $2.852B 24.28
Endo (ENDP) Ireland $2.176B 3.33
Heron Therapeutics (HRTX) United States $2.109B 0.00
Aerie Pharmaceuticals (AERI) United States $2.000B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.989B 0.00
Xencor (XNCR) United States $1.892B 0.00
Madrigal Pharmaceuticals (MDGL) United States $1.848B 0.00
Zogenix (ZGNX) United States $1.811B 0.00
Portola Pharmaceuticals (PTLA) United States $1.762B 0.00
PTC Therapeutics (PTCT) United States $1.738B 0.00
Corcept Therapeutics (CORT) United States $1.725B 25.32
Pacira Pharmaceuticals (PCRX) United States $1.646B 222.44
Theravance Biopharma (TBPH) Cayman Islands $1.508B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.494B 21.01
Arrowhead Pharmaceuticals (ARWR) United States $1.339B 0.00
TherapeuticsMD (TXMD) United States $1.216B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.166B 0.00
Esperion Therapeutics (ESPR) United States $1.154B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.030B 0.00
Tricida (TCDA) United States $0.925B 0.00
Radius Health (RDUS) United States $0.797B 0.00
ImmunoGen (IMGN) United States $0.760B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.644B 0.00
ChemoCentryx (CCXI) United States $0.629B 49.80
Karyopharm Therapeutics (KPTI) United States $0.599B 0.00
Siga Technologies (SIGA) United States $0.590B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.553B 0.00
Flexion Therapeutics (FLXN) United States $0.552B 0.00
Collegium Pharmaceutical (COLL) United States $0.524B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.484B 28.55
GlycoMimetics (GLYC) United States $0.466B 0.00
Odonate Therapeutics (ODT) United States $0.457B 0.00
Forty Seven (FTSV) United States $0.450B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.431B 0.00
Aptorum Group (APM) China $0.418B 0.00
ArQule (ARQL) United States $0.408B 0.00
Akebia Therapeutics (AKBA) United States $0.365B 0.00
Majesco Entertainment (PTE) United States $0.358B 0.00
Xeris Pharmaceuticals (XERS) United States $0.355B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.348B 0.00
CASI Pharmaceuticals (CASI) United States $0.347B 0.00
Concert Pharmaceuticals (CNCE) United States $0.333B 0.00
Lannett Co Inc (LCI) United States $0.300B 2.60
OptiNose (OPTN) United States $0.296B 0.00
KalVista Pharmaceuticals (KALV) United States $0.288B 0.00
Dermira (DERM) United States $0.286B 0.00
Minerva Neurosciences (NERV) United States $0.275B 0.00
Tapimmune (MRKR) United States $0.272B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.269B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.268B 0.00
Depomed (ASRT) United States $0.267B 9.95
IMV INC (IMV) Canada $0.264B 0.00
Aclaris Therapeutics (ACRS) United States $0.260B 0.00
Mast Therapeutics (SVRA) United States $0.259B 0.00
Translate Bio (TBIO) United States $0.250B 0.00
Tyme Technologies (TYME) United States $0.249B 0.00
Opexa Therapeutics (ACER) United States $0.243B 0.00
Aldeyra Therapeutics (ALDX) United States $0.234B 0.00
Dova Pharmaceuticals (DOVA) United States $0.232B 0.00
TAIWAN LIPOSOME (TLC) Taiwan $0.230B 0.00
Affimed (AFMD) Germany $0.221B 0.00
Aratana Therapeutics (PETX) United States $0.215B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.201B 0.00
Galectin Therapeutics (GALT) United States $0.195B 0.00
MEI Pharma (MEIP) United States $0.194B 0.00
Zafgen (ZFGN) United States $0.175B 0.00
Aquestive Therapeutics (AQST) United States $0.173B 0.00
Recro Pharma (REPH) United States $0.172B 0.00
Calithera Biosciences (CALA) United States $0.170B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.165B 0.00
Ocular Therapeutix (OCUL) United States $0.163B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.155B 0.00
Molecular Templates (MTEM) United States $0.155B 0.00
Nature's Sunshine Products (NATR) United States $0.154B 0.00
ElectroCore (ECOR) United States $0.148B 0.00
Redhill Biopharma (RDHL) Israel $0.147B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.147B 0.00
Adherex Technologies (FENC) United States $0.139B 0.00
Ardelyx (ARDX) United States $0.139B 0.00
Neon Therapeutics (NTGN) United States $0.138B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.136B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.135B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.131B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.130B 0.00
Jounce Therapeutics (JNCE) United States $0.124B 0.00
MediWound (MDWD) Israel $0.118B 0.00
Cardiome Pharma (CORV) Canada $0.115B 0.00
Champions Oncology (CSBR) United States $0.115B 0.00
ProNAi Therapeutics (SRRA) Canada $0.108B 0.00
CHINA SXT PHARM (SXTC) China $0.106B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.094B 0.00
DURECT (DRRX) United States $0.094B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.091B 0.00
Iterum Therapeutics (ITRM) Ireland $0.083B 0.00
Natural Alternatives (NAII) United States $0.083B 8.18
Nivalis Therapeutics (ALPN) United States $0.079B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.074B 0.00
CTI BioPharma (CTIC) United States $0.071B 0.00
Infinity Pharmaceuticals (INFI) United States $0.071B 0.00
Avenue Therapeutics (ATXI) United States $0.070B 0.00
KemPharm (KMPH) United States $0.070B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.069B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.069B 0.00
Immune Design (IMDZ) United States $0.068B 0.00
Otonomy (OTIC) United States $0.062B 0.00
BioLineRx (BLRX) Israel $0.062B 0.00
Neos Therapeutics (NEOS) United States $0.061B 0.00
Achaogen (AKAO) United States $0.060B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.058B 0.00
Melinta Therapeutics (MLNT) United States $0.057B 0.00
Genocea Biosciences (GNCA) United States $0.051B 0.00
Forward Pharma (FWP) Denmark $0.050B 0.00
Mannatechorporated (MTEX) United States $0.046B 0.00
ContraFect (CFRX) United States $0.044B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.043B 0.00
Capnia (SLNO) United States $0.036B 0.00
NOVAN INC (NOVN) United States $0.036B 0.00
Lipocine (LPCN) United States $0.036B 0.00
SCYNEXIS (SCYX) United States $0.036B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
Heat Biologics (HTBX) United States $0.032B 0.00
PharmAthene (ALT) United States $0.025B 0.00
ESSA Pharma (EPIX) Canada $0.025B 0.00
Trillium Therapeutics (TRIL) Canada $0.025B 0.00
Biomerica (BMRA) United States $0.022B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.022B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.021B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.020B 0.00
Citius Pharmaceuticals (CTXR) United States $0.020B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.020B 0.00
Pain Therapeutics (PTIE) United States $0.019B 0.00
Xenetic Biosciences (XBIO) United States $0.019B 0.00
HANCOCK JAFFE (HJLI) United States $0.019B 0.00
Cyanotech (CYAN) United States $0.018B 0.00
Jaguar Animal Health (JAGX) United States $0.018B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.016B 0.00
Aviragen Therapeutics (VXRT) United States $0.014B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.014B 0.00
Skyline Medical (AIPT) United States $0.013B 0.00
Shineco (TYHT) China $0.012B 1.27
Onconova Therapeutics (ONTX) United States $0.011B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.011B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Regulus Therapeutics (RGLS) United States $0.010B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.009B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.007B 0.00
Apricus Biosciences (APRI) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
Intellipharmaceutics (IPCI) Canada $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Midatech Pharma (MTP) United Kingdom $0.005B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.004B 0.00
Bio Blast Pharma (ORPN) Israel $0.003B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.003B 0.00
Bio-Path Holdings (BPTH) United States $0.001B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00